D-0535-2025 Class II

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

FDA drug recall D-0535-2025 was initiated by Imprimis NJOF, LLC on Jul 9, 2025 and is designated Class II. Reason for recall: Sub-Potent Drug: Subpotent assay results during stability testing. Affected quantity: 6,880 vials.

Recall details

Product Type
Drugs
Report Date
Jul 30, 2025
Initiation Date
Jul 9, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6,880 vials

Product description

Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01

Reason for recall

Sub-Potent Drug: Subpotent assay results during stability testing.

Distribution pattern

Nationwide in the USA

Code information

Lot: 24DEC017, Exp. 07/12/2025.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0535-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0535-2025. Report a data issue: hello@regdatalab.com.